The OX1 patent relates to a new salt form found to be useful to increase the purity of the compound during manufacture.
The company has also received a similar notice from the Israeli patent office for the RECALL-VAX platform technology that underlies RV03,a bi-specific vaccine targeting beta amyloid and delta tau for the treatment and prevention of Alzheimer’s disease.
The company said patents for RECALL-VAX have been granted in the US, Europe and Japan.
Intellect Neurosciences chairman and CEO Daniel Chain said the new patent allowances underscore the depth of the company’s patent portfolio comprising of some fifteen patent estates covering its platform technologies and products in development.
"We have entered into four new license agreements since 2008, and continue to attract interest from global pharmaceutical companies interested in collaborating on our programs for promising next generation therapies for the treatment of neurodegenerative diseases," Chain added.